SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor¶
Why this mattered¶
This paper mattered because it turned SARS-CoV-2 from a newly sequenced threat into a mechanistically tractable virus. By showing that the virus used ACE2, the known SARS-CoV receptor, and required TMPRSS2-mediated spike priming for efficient entry into lung cells, Hoffmann and colleagues anchored COVID-19 biology in a specific host-cell pathway rather than a generic model of respiratory viral infection. That connection immediately clarified why prior SARS research was relevant, while also giving researchers concrete variables to measure: ACE2 expression, TMPRSS2 expression, spike-receptor binding, and protease-dependent activation.
The result made several lines of work newly actionable. It supplied a rationale for pseudovirus entry assays, airway-cell tropism studies, ACE2/TMPRSS2 expression maps, and animal or organoid models engineered around the correct entry factors. It also gave drug discovery a host-directed target: camostat mesylate, a clinically used TMPRSS2 inhibitor, blocked SARS-CoV-2 entry in the authors’ experiments. Although later clinical experience with protease inhibitors such as camostat was more limited than the early in vitro promise suggested, the conceptual shift was durable: blocking entry could be studied as a defined intervention rather than as broad antiviral speculation.
The paper also helped frame later breakthroughs in vaccines, antibodies, and variant biology. Once spike-mediated ACE2 entry was established as central, neutralizing-antibody studies could focus on blocking receptor engagement or spike conformational changes, and variant surveillance could interpret mutations in terms of ACE2 affinity, spike processing, and cell-entry route. In that sense, the paper was not the final word on COVID-19 pathogenesis, but it set the experimental grammar for much of the field: SARS-CoV-2 would be understood first through the interaction between spike, ACE2, and host proteases.
Abstract¶
(no abstract available)
Related¶
- cite → Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China — The SARS-CoV-2 entry paper links its ACE2/TMPRSS2 mechanism study to early clinical characterization of COVID-19 patients in Wuhan.
- cite → Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR — The SARS-CoV-2 entry paper relies on RT-PCR detection methods for identifying 2019-nCoV infections.
- cite → A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster — The SARS-CoV-2 entry paper connects its cell-entry mechanism to evidence that the virus spreads by human-to-human transmission.
- cite → A pneumonia outbreak associated with a new coronavirus of probable bat origin — The SARS-CoV-2 entry paper builds on the identification of the new bat-related coronavirus causing the pneumonia outbreak.